No, I do not have any real thoughts on King as a takeover play.KG is in a position where the potential to improve definitely exists, but there are numerous short-term problems such as slowing sales on their main product. This might make the firm attractive to some other moderate sized Pharma companies.I would just like to see King get their operating act together.-- Mark --
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat